Pressure BioSciences Partners with Academic and Industry Leaders to Revolutionize Food, Wellness and Biomedical Spaces

Image Provided By Pixabay

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Pressure BioSciences, Inc. PBIO, the pioneer behind innovative, broadly applicable pressure-based technologies, has been aggressively pursuing strategic partnerships with academic and industry leaders, including Ohio State University and a range of biopharmaceutical and biotechnology companies, from recent start-ups to time-honored multibillion-dollar global entities. 

Through these partnerships, Pressure BioSciences (PBI) hopes to roll out its pressure-based technologies across the wide range of industries where it has the most potential to make an impact. Here are some of those existing and planned partnerships and what consumers and investors can expect to see from them.

Ohio State University Partnership Forms Food Industry Consortium

One of the most exciting and clearly promising partnerships PBI has entered into is its partnership with Ohio State University. Together, this renowned academic institution and publicly traded company have formed the food industry consortium. Food and beverage companies who join the member-based consortium will receive a first look right at PBI’s patented Ultra Shear Technology (UST) platform.

The UST platform, which produces high quality, long-term, shelf-stable nanoemulsions of oil-based nutrients and ingredients, has broad and potentially lucrative applications across the food and beverage space. Two of the leading breakthroughs driven by the new tech are the nanoemulsions it can process of CBD oil and the highly potent antioxidant, astaxanthin. These more potent and stable nanoemulsions are expected to soon be infused into food and beverages to offer health and wellness products to consumers worldwide.

The financial dues paid by consortium members will go toward funding additional research, including the final development of an industrial scale prototype of the UST platform that could be used to mass produce high quality nanoemulsions in multiple areas, making the tech viable for even the largest clients in the industry. PBI aims to sign at least two major food and beverage licensing agreements through this consortium before the end of 2021.  The Company is also talking to potential licensees in the cosmetics, nutraceutical, and pharmaceutical areas.

Major BaroFold Licensing Partnerships Work Toward Groundbreaking New Treatments

Predating its innovative UST platform, PBI’s BaroFold technology offers similar pressure-based technology that has the potential to revolutionize the biomedical space. Foe example, through licensing partnerships for its BaroFold platform, PBI is helping to advance the development of protein-based drugs, with the goal of helping such drugs get to the market that might never get commercialized through usual means.

Protein-based drugs are exceedingly important because they can be better targeted and often cause fewer adverse effects than chemical-based drugs in many diseases — especially cancer, inflammatory diseases and autoimmune disorders. 

One of the key issues holding the industry back, though, is the challenge of developing these drugs, especially at large commercial scale. The process of proper folding and combining proteins is difficult and riddled with multiple points for potential error. BaroFold has the potential to eliminate those challenges and provide a consistent, efficient process for developing stable, potent protein-based therapeutics at almost any reasonable commercial scale. 

By licensing its platform to partners in the biopharmaceutical space, PBI can not only do its part to advance medicine by offering a scalable, efficient way to mass produce these more effective and safer protein-based drugs for patients around the world, but it can also collect recurring royalty fees as it does so, thus securing its piece of this estimated $228 billion market. 

PBI has already doubled its client base this year, signing new multibillion-dollar pharmaceutical clients and advancing one client to a higher production scale Stage 2 contract. It aims to advance at least one more client to a Stage 2 contract before the end of 2021.

Leica Microsystems Partnership Could Revolutionize Diagnostics

PBI announced a co-marketing agreement with Leica Microsystems this past March. The respected microscope manufacturer - one of the oldest and largest in the world - will work with PBI to develop an advanced diagnostics process that researchers can use to better detect cancer and monitor disease progression in tissue biopsy samples. This work involves collaboration among Leica, PBI, and Dr. Thomas P. Conrads of the Inova Health System (Annabdale, VA), one of the top cancer experts in the U.S.

By pairing Leica’s new laser microscopes with PBI’s Pressure Cycling Technology (PCT) platform, researchers can laser cut a precise section of a patient’s biopsy tissue, break it down into its component proteins and nucleic acids with the PCT platform, and then send it to a mass spectrometer to be analyzed for biomarkers of disease. Currently in the planning stages, Dr. Conrads, Leica and PBI aim to unveil this innovative collaborative workflow process by the end of 2021.

PBI is on a mission and making measurable progress in its goal to use its patented, pressure-based technology platforms to revolutionize the food, wellness, and biomedical spaces.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.